Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Phase I and pharmacokinetic study of oral paclitaxel.

Phase I and pharmacokinetic study of oral paclitaxel. To investigate dose escalation of oral paclitaxel in combination with dose increment and scheduling of cyclosporine (CsA) to improve the systemic exposure to paclitaxel and to explore the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of clinical oncology : official journal of the American Society of Clinical Oncology Pubmed

Phase I and pharmacokinetic study of oral paclitaxel.

Malingré, M M; Terwogt, J M; Beijnen, J H; Rosing, H; Koopman, F J; van Tellingen, O; Duchin, K; Huinink, W W; Swart, M; Lieverst, J; Schellens, J H
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , Volume 18 (12): -2392 – Jul 18, 2000
Download PDF

Phase I and pharmacokinetic study of oral paclitaxel.


Abstract

To investigate dose escalation of oral paclitaxel in combination with dose increment and scheduling of cyclosporine (CsA) to improve the systemic exposure to paclitaxel and to explore the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT).

Loading next page...
 
/lp/pubmed/phase-i-and-pharmacokinetic-study-of-oral-paclitaxel-NUXwpV0V3I

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0732-183X
DOI
10.1200/JCO.2000.18.12.2468
pmid
10856107

Abstract

To investigate dose escalation of oral paclitaxel in combination with dose increment and scheduling of cyclosporine (CsA) to improve the systemic exposure to paclitaxel and to explore the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT).

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology – Pubmed

Published: Jul 18, 2000

There are no references for this article.